ClinicalTrials.gg

Program

SHR-7787

A development code. Also written as “SHR-7787 injection”.

In Jiangsu HengRui Medicine's pipeline, DLL3/CD3. Its studies are led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Sep 14, 20241 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningphase 2since Sep 14, 2024Sep 14, 2024Dec 2026phase 2 · NCT06605222
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-7787, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2024First study: phase 2 study in Advanced Solid TumorsFirst studyNCT06605222 · 201 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Solid TumorsNCT06605222

TargetBeta

“DLL3/CD3”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
gocatamigMerckphase 34
clesitamigHoffmann-La Rochephase 12
HLX3901Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06605222Advanced Solid Tumors · China2RecruitingDec 2026201

How it is read

Names in the registry

  • “SHR-7787 injection”, 1 entry

Codes read as this program: SHR7787.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.